Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients
Tóm tắt
Treatment of retinitis by cytomegalovirus (CMV) in AIDS patients requires frequent repetitive injections of intravitreal ganciclovir (GCV). This study was undertaken to establish experimentally whether the intravitreal application of liposomally-entrapped GCV could prolong intraocular therapeutic levels when compared with the intravitreal injection of free GCV, and the clinical effectiveness of this approach in AIDS patients. Intraocular concentration of GCV was determined by means of an ELISA test in rabbit vitreous 2, 3, 7, and 14 days after a single intravitreal injection of either different doses of the free drug (0.2–20 mg) or 1 mg of liposomally-entrapped GCV. After 72 h, only the vitreous of rabbits injected with doses of free GCV greater than or equal to 5 mg showed therapeutic levels of the drug; no GCV was detected after 72 h with any of the doses applied. Moreover, the microscopic study revealed GCV-induced damage in retinal structures in the animals injected with a free GCV dose greater than or equal to 15 mg. Intravitreal injection to rabbits of 1 mg of liposomally-encapsulated GCV showed no retinal toxicity at any of the time points studied, and therapeutic levels were detected up to 14 days after injection (4.67 ± 0.39 μg/ml). Five AIDS patients suffering CMV retinitis were injected with 0.5 mg of liposomally-entrapped GCV (2 mg of lecithin). Complete remission of the CMV retinitis was observed already at the third injection of 0.5 mg GCV (one per week) and relapse did not occur during the 2–4 month follow-up of the patients. In view of the results presented, it can be concluded that intravitreal injection of liposomally-encapsulated GCV increases the time period required for reinjections in the treatemnt of CMV retinitis.
Tài liệu tham khảo
Pepose JS, Holland GN, Nestor MS, Cochran AJ, Foos RY. Acquired immunodeficiency syndrome: Pathogenic mechanism of ocular disease. Ophthalmology 1985; 92: 472–484.
GEMU (Grupo Español Muticéntrico para el Estudio de las Uveítis) Manifestaciones oftalmológicas del SIDA en España. Arch Soc Esp Oftalmol 1992 (in press).
Daikos GL, Pulido J, Kathpalia SB, Jackson GG. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosupression. Br J Ophthalmol 1988; 72: 521–524.
Henry K, Cantrill H, Pfletcher C, Chinnok B, Balfour HH. Use of intravitreal ganciclovir (dihydroxypropoymethylguanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103: 17–23.
Obrador P, Lacruz J, Lopez A, Díaz-Llopis M. Ganciclovir intravítreo versus intravenoso en la retinitis por CMV del SIDA. Stadium Ophthalmol 1990; 12: 57–63.
Bangham AD. Membrane models with phospholipids. Prog Biophys Mol Biol 1968; 18: 31–37.
Vila AO, Molina FJ, Figueruelo JE. Patent #P8903526, Spain (1989).
Llácer C, Martos MJ, Vila AO, Molina FJ. Determinación de los parámetros que controlan la formación de liposomas de lecitina de heuvo. An Quím 1992 (in press).
Dieguez P, Vila AO, Molina FJ. Modification of some aspects of HDC techniques. An Quím 1990; 86: 122.
Molina FJ, Vila AO, Dieguez P, Figueruelo JE. Hydrodynamic chromatography for characterization and purification of liposomes. HRC 1989; 12: 560–561.
Cebamanos F, Vila AO, Dieguez P, Figueruelo JE, Molina FJ. Modified hydrodynamic chromatography and its applications to liposomes. HRC 1990; 13: 583–584.
Ussery FM, Gibson SR, Conklin RH, Piot DF, Stool EW, Conklin AJ. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 1988; 95: 640–648.
Tapedalli SM, Quinn RP, Averett DR. Comparative ELISA to quantitate acyclovir ACV levels in human plasma and urine samples. Fed Proc 1985; 44: 1122.
Wellcome B. Burroughs Wellcome Comprehensive Information for Investigators of BW B759U. (1984)
Runger-Brändle E, Roux L, Leuenberger PM. Bilateral acute retinal necrosis (BARN): Identification of the presumed infectious agent. Ophthalmology 1984; 91: 1684–1685.
Schulman J, Peyman GA, Horton MB. Intraocular 9-[2-hydroxy-1-(hydroxy-methyl)- ethoxy-methyl]-guanine levels after intravitreal and subconjunctival administration. Ophthalmic Surg 1986; 17: 429–434.
Smee DF, Martin JC, Verheyden JPH. Antiherpes virus activity of the acyclic nucleoside 9–1,3-dihydroxy-2-propoxymethylguanine. Antimicrobial Agents Chemother 1983; 23: 676–682.
Pulido J, Peyman GA, Lesar T, Vernot J. Intravitreal toxicity of hydroxyacylovir (BW-B759U): A new antiviral agent. Arch Ophthalmol 1985; 103: 840–841.
Schulman J, Peyman GA, Horton MB, Liu J, Barber JC, Fiscella R, Miranda P. Intraocular penetration of a new antiviral agent, hydroxyacyclovir (BW-B759U). Jpn J Ophthalmol 1986; 30: 116–124.
Heery S. High-dose intravitreal ganciclovir for cytomegalovirus retinitis. Aus New Zeal J Ophthalmol 1989; 17: 405–408.
Yoshimuzi MO, Lee D, Vinci V, Fajardo S. Ocular toxicity of multiple intravitreal DHPG injections. Gräfe's Arch Clin Exp Ophthamol 1990; 228: 350–355.
Shaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 1982; 21: 220–227.
Smolin G, Okumoto M, Feiler S, Condon A. Idoxuridine-liposome therapy for herpes simplex keratitis. Am J Ophthalmol 1981.
Lee VHL, Urrea PT, Smith RE, Schanzlin DJ. Ocular drug bioavailability from topically applied liposomes. Surv Ophthalmol 1985; 29: 335–348.
Alvarado JA. The use of liposome encapsulated 5-fluoro-orotate for glaucoma surgery. Trans Am Ophthalmol Soc 1989; 87: 489.
Khoobehi B, Peyman GA, McTurnan WG, Niesman MR, Magin RL. Externaly triggered release of dye and drugs from liposomes into the eye. Ophthalmology 1988; 95: 950–955.
Presant CA, Blayney D, Profitt RT, Turner AF, Williams LE, Nadal HI, Kennedy P, Wisserman CH, Gala K, Crossley RJ, Creiss SJ, Ksionsky GE, Presant SL. Visualización del sarcoma de Kaposi y del linfoma en el SIDA mediante liposomas marcados con Indio-111. The Lancet (Spanish edition) 1990; 335: 1307–1309.
Liu KR, Peyman GA, She SCH, Niesman MR, Khoobehi B. Reduced toxicity of intravitreally injected liposome-encapsulated cytarabine. Ophthalmic Surg 1989; 20: 358–360.
Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, Mani H. Toxicity and clearance of a combination of liposome encapsulated ganciclovir and trifluridine. Retina 1989; 9: 232–236.
Fitzgerald P, Hadgraft J, Kreuter J, Wilson CG. A scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987; 40: 81–84.
Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987; 28: 893–896.
Peyman GA, Khoobehi B, Tawakol M. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina 1987; 7: 227–229.
Peyman GA, Charles HC, Liu R, Khoobehi B, Niesman M. Intravitreal liposomeencapsulated drugs: a preliminary human report. Int Ophthalmol 1988; 12: 175–182.